Korean J Urol.  1993 Feb;34(1):35-50.

New penile squamous carcinoma cell line(CUPE-1): Characterization, tumor marker(TA-4) and growth factor study

Affiliations
  • 1Department of Urology, College of Medicine, Chung-Ang University, Seoul, Korea.
  • 2Department of Pathology, College of Medicine, Chung-Ang University, Seoul, Korea.

Abstract

Chung-Ang University Penile Squamous Carcinoma cell line (CUPE-1) was established from a lymph node metastasis of human penile squamous cell carcinoma (SCC). CUPE-1 grew as adherent monolayer with a defined doubling time of 24 hours. CUPE-1 showed epithelial characterization on inverted and light microscopy and showed well developed desmosomes and tonofilaments or electron microscopy. CUPE preserved cytokeratin on immunohistochemical staining. CUPE expressed the receptor of epidermal growth factor (EGF), which stimulated the proliferation of CUPE-1 CUPE-1 showed strong tumorigenecity and/or metastatic ability when subcutaneously and intraperitoneally implanted into the nude mouse. CUPE-1 produced tumor associated antigen-4 (TA-4), a tumor marker for SCC of uterine cervix, both in vitro and in vivo. In addition, the serum level-of TA-4 were specifically increased in patients with penile SCC. These results indicate that CUPE-1 retains the characteristics of human penile SCC and could provide an excellent model for the basic research and development of new therapeutic modalities of penile cancer, and that TA-4 may become a valuable tumor marker of penile SCC.

Keyword

Penile Squamous carcinoma cell line (CUPE-1); Characterization; TA-4; Growth factor

MeSH Terms

Animals
Carcinoma, Squamous Cell*
Cell Line
Cervix Uteri
Desmosomes
Epidermal Growth Factor
Female
Humans
Intermediate Filaments
Keratins
Lymph Nodes
Male
Mice
Mice, Nude
Microscopy
Microscopy, Electron
Neoplasm Metastasis
Penile Neoplasms
Epidermal Growth Factor
Keratins
Full Text Links
  • KJU
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr